Tonix Pharmaceuticals Holding Corp.TNXPEarnings & Financial Report

Nasdaq · pharmaceutical industry

Tonix Pharmaceuticals is a pharmaceutical company based in Chatham, New Jersey that focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project.

Revenue

$3.3M

Gross Profit

$1.9M

Operating Profit

$-33.1M

Net Profit

$-32.0M

Gross Margin

58.4%

Operating Margin

-1005.1%

Net Margin

-972.9%

YoY Growth

16.6%

EPS

$-3.59

Financial Flow

Tonix Pharmaceuticals Holding Corp. Q3 2025 Financial Summary

Tonix Pharmaceuticals Holding Corp. reported revenue of $3.3M for Q3 2025, with a net profit of $-32.0M (-972.9% margin). Cost of goods sold was $1.4M, operating expenses totaled $35.0M.

Key Financial Metrics

Total Revenue	$3.3M
Net Profit	$-32.0M
Gross Margin	58.4%
Operating Margin	-1005.1%
Report Period	Q3 2025

Tonix Pharmaceuticals Holding Corp. Annual Revenue by Year

Tonix Pharmaceuticals Holding Corp. annual revenue history includes year-by-year totals (for example, 2024 revenue was $10.1M).

Year	Annual Revenue
2024	$10.1M
2023	$7.8M
2022	$0

Income Statement

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Revenue	$3.8M	$2.5M	$2.2M	$2.8M	$2.6M	$2.4M	$2.0M	$3.3M
YoY Growth	N/A	N/A	N/A	-29.3%	-31.7%	-2.1%	-9.5%	16.6%

Balance Sheet

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Assets	$154.5M	$135.3M	$70.3M	$95.0M	$162.9M	$192.9M	$187.4M	$252.4M
Liabilities	$48.9M	$27.2M	$28.2M	$20.8M	$23.3M	$12.5M	$19.4M	$21.3M
Equity	$105.5M	$108.1M	$42.1M	$74.2M	$139.6M	$180.4M	$168.0M	$231.1M